SLNO — SOLENO THERAPEUTICS INC

Nasdaq · Health Care · Pharmaceuticals · CIK 1484565 ·
Last close
$53.01
Market Cap
$2.76B
52W High
$53.01
52W Low
$29.43
ADV30
3,349,453
Next earnings
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. As of May 18, 2026, Soleno Therapeutics, Inc. operates as a subsidiary of Neurocrine Biosciences, Inc.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 94,603,000 93,405,000 31,762,000 31,378,000 608,388,000 133,026,000 112,588,000
Dec 2025 91,730,000 90,867,000 40,431,000 43,358,000 563,830,000 70,106,000 113,715,000
Sep 2025 66,018,000 64,877,000 22,719,000 26,013,000 599,895,000 246,662,000 105,090,000
Jun 2025 32,657,000 31,961,000 -5,424,000 -4,708,000 332,306,000 76,497,000 92,166,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$46,798,000
Investing CF
$-201,781,000
Financing CF
$137,161,000
CapEx
$-73,000
Dividends Paid
Buybacks
EPS Diluted TTM
$0.23
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-431,370,000
Inventory
$15,024,000
Receivables
$28,208,000
ST Investments
$235,366,000
EBIT TTM
$26,366,000
Pretax Income TTM
$20,890,000
Interest Exp TTM
$5,476,000
Analysts
8

Yahoo Snapshot (yfinance, live)

Total Revenue
$285,008,000
EBITDA
$91,515,000
Free Cash Flow
$91,667,624
Enterprise Value
$2,561,566,976
Total Cash
$255,599,008
Total Debt
$54,277,000
Shares Out
52,120,147
Trailing EPS
$1.93
Book Value
$8.61
ROE
26.4%
ROA
12.1%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 190,405,000 14,950,000 20,890,000 563,830,000 113,715,000 46,798,000
Dec 2024 0 -184,429,000 -175,850,000 330,972,000 85,859,000 -69,096,000
Dec 2023 0 -38,670,000 -38,988,000 180,691,000 23,184,000 -24,940,000
Dec 2022 0 -25,109,000 -24,067,000 26,497,000 16,149,000 -20,781,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-2.27

Peers — same industry

TickerNameMarket CapLastDaily %
ALMS ALUMIS INC. $2.76B $22.33
SUPN SUPERNUS PHARMACEUTICALS, INC. $2.77B $47.77
KLRA Kailera Therapeutics, Inc. $2.79B $21.57
GPCR Structure Therapeutics Inc. $2.81B $39.58
ARQT Arcutis Biotherapeutics, Inc. $2.64B $21.11

News headlines (Yahoo Finance, 1h cache)

Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
2026-05-18 12:46 · Yahoo
Soleno Merger With Neurocrine Puts Profitability And Valuation In Focus
2026-05-11 03:14 · Yahoo
Neurocrine Biosciences Q1 Earnings Call Highlights
2026-05-06 01:35 · Yahoo
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
2026-05-05 20:01 · Yahoo
Soleno Therapeutics (SLNO) Surges Nearly 60% In April Amid Neurocrine Acquisition Deal
2026-05-01 14:46 · Yahoo
Folia Health Launches “BRAVE-PWS” Study to Better Understand the Real-World Experience of Prader-Willi Syndrome Caregivers
2026-04-15 12:00 · Yahoo
Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why
2026-04-08 15:23 · Yahoo
Neurocrine Soleno Deal Adds Vykat XR And Alters Valuation Story
2026-04-07 14:08 · Yahoo
Arm downgraded, Arista Networks upgraded: Wall Street's top analyst calls
2026-04-07 13:47 · Yahoo
Company News for Apr 7, 2026
2026-04-07 13:33 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.